CT-388
Enith2
Roche · Phase 3 · Recruiting · Enrollment 1600
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Arm 1: Placebo | Obesity + T2D | n/r | n/r | n/r | n/r |
| Arm 2: Enicepatide Dosing Regimen 1 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Arm 3: Enicepatide Dosing Regimen 2 | Obesity + T2D | n/r | n/r | n/r | n/r |
| Arm 4: Enicepatide Dosing Regimen 3 | Obesity + T2D | n/r | n/r | n/r | n/r |